Trump Buys SpaceX Shares After Record IPO 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Add as a preferred source on Google
EAST RUTHERFORD, N.J., April 19, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices. Cambrex’s commitment to the environment, health and safety underpins our activities across our sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to our ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com. In connection with today’s announcement, Trillium Asset Management, LLC informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex has appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact:
Tom Vadaketh
Executive VP & CFO
Tel: +201 804 3033
Email: [email protected]
